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Research
AbstrACt
Objectives Evaluation of the demonstrator phase and 
first wave roll-out of the National Health Service (NHS) 
Diabetes Prevention Programme (DPP) in England. 
To examine: (1) intervention design, provision and 
fidelity assessment procedures; (2) risk assessment 
and recruitment pathways and (3) data collection for 
monitoring and evaluation. To provide recommendations 
informing decision makers on programme quality, 
improvements and future evaluation.
Design We reviewed programme documents, mapping 
against the NHS DPP specification and National Institute 
for Health and Care Excellence (NICE) public health 
guideline: Type 2 diabetes (T2D) prevention in people at 
high risk (PH38), conducted qualitative research using 
individual interviews and focus group discussions with 
stakeholders and examined recruitment, fidelity and data 
collection procedures.
setting Seven NHS DPP demonstrator sites and, 
subsequently, 27 first wave areas across England.
Interventions Intensive behavioural intervention with 
weight loss, diet and physical activity goals. The national 
programme specifies at least 13 sessions over 9 months, 
delivered face to face to groups of 15–20 adults with non-
diabetic hyperglycaemia, mainly recruited from primary 
care and NHS Health Checks.
Participants Participants for qualitative research were 
purposively sampled to provide a spread of stakeholder 
experience. Documents for review were provided via the 
NHS DPP Management Group.
Findings The NHS DPP specification reflected current 
evidence with a clear framework for service provision. 
Providers, with national capacity to deliver, supplied 
intervention plans compliant with this framework. 
Stakeholders highlighted limitations in fidelity assessment 
and recruitment and retention challenges, especially 
in reach and equity, that could adversely impact on 
implementation. Risk assessment for first wave eligibility 
differed from NICE guidance.
Conclusions The NHS DPP provides an evidence-based 
behavioural intervention for prevention of T2D in adults at 
high risk, with capacity to deliver nationally. Framework 
specification allows for balance between consistency 
and contextual variation in intervention delivery, with 
session details devolved to providers. Limitations in 
fidelity assurance, data collection procedures and 
recruitment issues could adversely impact on intervention 
effectiveness and restrict evaluation.
IntrODuCtIOn
‘Healthier You’, the National Health Service 
(NHS) Diabetes Prevention Programme 
(DPP) offers adults in England at high risk 
of type 2 diabetes (T2D) an evidence-based 
behavioural intervention to prevent or delay 
T2D onset.1 Led by a partnership of NHS 
England, Public Health England (PHE) and 
Diabetes UK, the NHS DPP is being imple-
mented in phases, with plans for 100 000 
places to be made available across England 
by 2020 and each year thereafter.1 A brief 
description of the intervention is provided in 
box 1. This initiative was part of the NHS Five 
strengths and limitations of this study
 ► Evidence-based guidelines informed a structured 
review of National Health Service Diabetes 
Prevention Programme  (NHS DPP) service 
specification and intervention provider documents, 
covering the whole implementation span from 
raising awareness to follow-up.
 ► Purposive sampling ensured that a spread of 
stakeholder experience across four groups (local 
commissioners, referrers, intervention providers 
and service users), and from different areas of 
the country, was included in qualitative research 
interviews and interactive focus group discussions.
 ► We made recommendations to the NHS DPP 
Management Group on intervention fidelity, 
risk assessment and recruitment procedures to 
strengthen future implementation and support 
future definitive evaluation.
 ► Opportunities to maximise learning from early phase 
implementation of the NHS DPP were limited by 
the pace of roll-out set against the timescale of the 
evaluation.
 ► Quantitative outcome data analyses and reporting 
was beyond the scope of this study.
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Year Forward View,2 which emphasised the importance of 
prevention and public health to the sustainability of the 
NHS and economic prosperity of Britain.
Tackling the increase in T2D is vital to the sustain-
able future of the NHS.3 In 2015, 3.8 million people in 
England aged over 16 years had diabetes.3 Prevalence 
of diabetes is greater in areas of socioeconomic depri-
vation,4 and people from south Asian and black ethnic 
groups are twice as likely to have diabetes compared 
with people from white or other ethnic groups (15.2% vs 
8.0%, respectively).3 About 90% of people with diabetes 
have T2D, which is linked to obesity and largely prevent-
able. Costs to the NHS for T2D treatment are currently 
£8 billion each year, and T2D is increasingly affecting 
younger and working age people.5
Effectiveness of complex behavioural interventions, 
often referred to as lifestyle interventions, to prevent or 
delay T2D onset in people at high risk was first demon-
strated in randomised controlled trials (RCTs) in Finland6 
and the USA.7 These RCTs were conducted in adults with 
impaired glucose tolerance (IGT) (ie, blood glucose 
values between 7.8 mmol/L and 11.1 mmol/L 2 hours 
after a standard 75 g oral glucose tolerance test8). The first 
T2D prevention RCT in England was based on the Finnish 
Diabetes Prevention Study (DPS) protocol and demon-
strated a similar T2D risk reduction of 55% in the inter-
vention compared with the control group.9 Subsequently, 
studies in different populations have shown the beneficial 
effect of lifestyle intervention in reducing T2D onset in 
adults at high risk, including translational programmes 
delivered in primary care or community settings, some of 
which were implemented on a large scale.10 However, the 
risk reduction in translational programmes was generally 
less than in the early trials. Pooled T2D risk reduction 
of 26% in those receiving an intervention compared 
with usual care was reported in a recent review of prag-
matic lifestyle interventions for diabetes prevention in 
UK routine practice commissioned by PHE to inform the 
specification of the English NHS DPP.11
Demonstrator site phase and first wave implementation of the 
nHs DPP
In 2015, seven ‘demonstrator sites’ from across England 
were selected to provide a variety of T2D prevention 
programme models and populations, offering examples 
of intervention service delivery to inform subsequent 
NHS DPP development and roll-out. The first wave of the 
NHS DPP was then commissioned nationally, to be imple-
mented by a national and regional team, and delivered by 
four provider organisations that had capacity to deliver 
the intervention across England. First wave NHS DPP 
roll-out started in May 2016 in 10 of the first wave areas, 
where referrals to the programme began between June 
and September 2016. In June 2016, roll-out continued, to 
include the remaining 17 first wave areas where referrals 
to the programme began between August and November 
2016. First wave areas were invited to participate in 
mini-competitions that set out local context and related 
needs to inform local variations in intervention provision. 
The mandate for the first wave referred to generation of 
at least 10 000 referrals, with up to 20 000 NHS DPP places 
to be made available in 27 areas, across England.
Our independent formative evaluation, of the demon-
strator site phase and first wave implementation of the 
NHS DPP, was commissioned by the UK Department 
of Health to inform subsequent NHS DPP implemen-
tation and evaluation. We examined: (1) intervention 
design and provision, in relation to the evidence base, 
and procedures to assess intervention fidelity; (2) risk 
assessment procedures and recruitment pathways; and 
(3) data collection, monitoring and evaluation. We 
provided detailed and explicit recommendations, based 
on findings from the formative evaluation, to inform the 
national programme management group and other deci-
sion makers on programme quality, improvements and 
future implementation and evaluation.
MetHODs
Framework for evaluation
In planning the evaluation, we drew on the Medical 
Research Council (MRC) guidance for development and 
evaluation of complex interventions to improve health12 
and the MRC guidance for process evaluation of complex 
interventions to improve health.13 Evaluation methods 
included structured document review, comparing the 
programme with the recommendations in National Insti-
tute for Health and Care Excellence (NICE) PH38,10 and 
box 1 Description of the national Health service (nHs) 
Diabetes Prevention Programme (DPP) risk assessment 
and intervention
The NHS DPP, an evidence-based behavioural intervention to prevent 
or delay the onset of type 2  diabetes (T2D) in people at high risk, 
is being made available to adults in England, aged over 18 years 
with non-diabetic hyperglycaemia (NDH), who are mainly identified 
through primary care and NHS health checks. The programme is 
commissioned and funded nationally and implemented by national 
and regional teams. In the first wave of implementation, recruitment 
includes from existing NHS records of people with NDH. Eligibility is 
based on glycoslyated haemoglobin A1c (HbA1c) value 42–47 mmol/
mol (6.00%–6.49%) or a fasting plasma glucose FPG value 5.5–6.9 
mmol/L within the 12 months prior to referral. In the first wave of 
implementation, each of the four national provider organisations 
will also recruit from community settings in one of their allocated 
intervention sites. These community-based recruitment pilots 
are being evaluated. The NHS DPP evidence-based behavioural 
intervention is specified in accordance with a national framework, 
with core goals of weight loss, improved diet and increased physical 
activity, and with the use of behaviour change techniques in 
intervention delivery. The specification and provider contracts require 
the intervention to be delivered face to face to groups of 15–20 
adults with NDH over at least 13 sessions (totalling 16 hours) with a 
minimum of 9 months’ duration. The initial provider contract terms 
are for 2 years before contract renewal, which will provide the first 
opportunity for any major variation to the programme.
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qualitative research involving individual interviews and 
interactive focus group discussions with key stakeholders, 
including service users.14 In this paper, we report brief 
details of methods and key findings.
research governance and ethics
All interview and focus group participants gave written 
informed consent to take part. Research governance 
and reporting strategies were agreed between the evalu-
ation team and the UK Department of Health, Research 
Development Directorate (which commissioned the eval-
uation) and the National Institute for Health Research 
(NIHR) School for Public Health Research (which 
funded the research).
Methods to address objectives
Document review
We reviewed and appraised programme documentation 
by systematically mapping written information supplied 
by providers (using demonstrator site applications and 
first wave provider procurement prospectuses in sepa-
rate reviews) and the NHS DPP service specification, 
against recommendations in NICE guidance PH38,10 
equality indicators,15 16 fidelity,17 data collection and 
quality assurance procedures. We defined fidelity to mean 
‘intervention delivered as intended’ thus encompassing 
components of adherence to specification and compe-
tence to deliver the intervention.17
Patient involvement
Patients were involved in review of intervention materials 
designed for service users and the service user question-
naires that were drafted as part of this research.
Qualitative interviews and interactive focus-group workshop 
discussions
We used individual semistructured interviews (n=62), 
conducted mostly by telephone, and interactive focus 
group discussions, delivered through two full day work-
shops each with three by three parallel 1 hour sessions 
(total 18 hours), to explore stakeholder experiences.18 
Purposive sampling was used to obtain a spread of experi-
ence across four stakeholder groups: local commissioners, 
referrers (mostly healthcare professionals), intervention 
providers and deliverers, and service users (all service 
users were interviewed in the demonstrator site phase). 
Topics addressed included intervention provision (partic-
ipant experience, access and equity, fidelity of interven-
tion delivery and staff training), referral and recruitment 
pathways, data collection and sustainability of behaviour 
change.13 19 We used the NHS DPP logic model diagram, 
which detailed resources, actions and outcomes, as a 
visual aid in focus group discussions. All focus groups 
box 2 Continued
important just to keep up to date’. (Interview, intervention deliverer 12, 
female, age 30 years)
box 2 social factors, service specification and fidelity 
assurance: qualitative research themes and illustrative 
quotes
social factors
Benefit of group support: ‘It was just [being] in a group and that was 
good…we've made friends with each other. I think it helps’. (Interview, 
service user 18, female, age 76 years)
‘We’re all in the same boat, yes, it’s lovely. I’ll miss them when it’s 
finished’. (Interview, service user 4, female, age 52 years)
Challenge of socialising and behaviour change: ‘When you go to 
somebody’s home and they’ve invited you in and they’ve prepared a 
meal for you, it’s very difficult to say, “I won’t eat that. I can’t eat that. I 
shouldn’t eat that.” ’ (Interview, service user 3, female, age 61 years)
Influence on others: ‘Yes, I also got my brother into it you know, my 
older brother he started coming to the gym with me. Plus when this is 
over my wife is coming to the gym with me’. (Interview, service user 
16, male, age 67 years)
‘And they’re spreading the message… We know they go away, 
not only just talking to their family, but they take the ideas to the 
workplace, to their friends’ . (Focus group, workshop 1)
‘So their lives will be better, but also, maybe their friends and family 
might get a few tips, and they might be better’. (Interview, intervention 
deliverer 7, male, age 44 years)
service specification
Flexibility and use of intervention scripts: ‘The way the conversation 
goes with the patient determines, a lot of the time, which script you 
would base your (information) on, because quite often you’ll find the 
conversation will bring out something they’re not sure of’. (Interview, 
intervention deliverer 15, female, age 58 years)
Tailoring and adaptation: ‘You can use the national model and tailor it 
to the local one and look at the ethnicity and devise the programme 
accordingly to fit your community’. (Focus group, workshop 1)
‘You have to adapt the course for a whole range of intellectual 
abilities,… And different cultural understandings’. (Interview, local 
commissioner 1, female, age 57 years)
Progressive variation: ‘As people start to work through the backlog and 
people understand slightly more about what works and what doesn’t 
work there can be more variation’. (Focus group, workshop 2)
Fidelity assurance procedures
Staff qualities and training: ‘They don’t have to be diabetes specialists, 
but I think they need to be specialist trained in order to actually 
deliver a high level of intervention programme … you don’t want the 
confidence and authority without knowledge’. (Focus group, workshop 
1)
‘I think [the deliverer] is a very likeable person, easy to listen to and 
quite clearly was quite keen on her subject’. (Interview, service user 7, 
male, age 71 years)
‘I trained as a nurse. I’ve also done my level two gym instructor, level 
three GP exercise referral, currently studying towards level 4; dealing 
with diabetic and obese clients’. (Interview, intervention deliverer 12, 
female, age 30 years)
‘It’s behaviour change, motivational interviewing, brief advice, brief 
intervention and all those kinds of behaviour change qualifications and 
experience’. (Interview, intervention deliverer 1, male age 35 years)
Mentoring and refresher training: ‘I watched how other people deliver 
it, just to give myself a little bit more confidence, really’. (Interview, 
intervention deliverer 8, female, age 51 years)
‘I think refresher training is always good. Things are always changing, 
new research is coming out, there are new guidelines. So refreshing is 
Continued
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and interviews were digitally audio recorded, transcribed 
and analysed using the Framework method.18 Early find-
ings were used to inform later interviews and focus group 
discussions, with the aim of achieving thematic satura-
tion. Qualitative data were collected, coded and checked 
by AR, AH, LP, KB and MMM with use of NVivo V.10 to 
facilitate data management.20
Data collection for monitoring and evaluation
To inform subsequent evaluation of NHS DPP implemen-
tation and equity, we explored data collection and fidelity 
assessment procedures by comparing data collected in 
demonstrator site programmes and data in the NHS DPP 
‘minimum data set’ (ie, the list of data items that each 
national provider organisation in the first wave NHS DPP 
implementation was contractually committed to collect) 
with data requirements detailed in NICE PH38.10 We 
used qualitative research findings to develop tools for use 
in intervention feasibility, acceptability and fidelity assess-
ment, and we invited stakeholder feedback to refine these 
tools. We worked with a key provider contact to copro-
duce a flow chart of recruitment pathway data and exam-
ined T2D risk factors using risk scores validated in a UK 
population (QDiabetes,21 Cambridge Risk Score,22 the 
Finnish Diabetes Risk Score23 and the Diabetes-UK risk 
score).10
FInDIngs
The NHS DPP Management reported that: (1) from 1 
April 2015 to 31 March 2016: 6577 people at high risk 
were referred to the seven demonstrator site programmes 
(94% of the target) and of these 3165 people (48% of 
those referred) started the intervention; (2) from 1 April 
2016 to 31 March 2017: 3170 people were referred to 
the four ongoing demonstrator site programmes and of 
these 2220 people (71% of those referred) started the 
intervention; and (3) from 1 April 2016 to 31 March 
2017: 43 606 people with NDH were referred to first wave 
programmes (116% of the target). Given the expected 
time lag between referral intervention uptake and data 
monitoring, the management group reported that 49% of 
those referred up to 31st January 2017 had attended the 
initial programme assessment by 31 March 2017.24 The 
management group also reported that financial support 
had been given to local health economies to facilitate 
demonstrator site programmes and first wave implemen-
tation of the NHS DPP.
Intervention provision, in relation to the evidence base, and 
procedures to assess fidelity of intervention delivery
We noted discrepancies between the detailed guidance 
on behaviour change techniques (BCTs) in NICE PH3810 
and the sparse information on BCTs in the draft NHS DPP 
service specification that was supplied to us during the 
demonstrator phase. However, the NHS DPP service spec-
ification was updated for the first wave to include more 
detail on BCTs and a theory of change13 (logic model). 
First wave provider documents linked standard BCTs with 
their expected mechanisms of action, BCTs for sustained 
behaviour change were often included and all providers 
detailed staff training on behaviour change strategies and 
use of theory-driven BCTs. Additional detailed descrip-
tion of intervention component mapping are provided 
as appendix A (online supplementary file 1). Interven-
tion fidelity procedures, including staff qualifications 
and training, were assigned as provider responsibilities. 
All first wave provider documents set out dietary and 
physical activity advice that complied with the NHS DPP 
service specification (as was required in the procurement 
process) and included detailed session plans with infor-
mation about weight loss and regular weighing of partici-
pants. Intervention duration and intensity also complied 
with the service specification, although session distribu-
tion differed between providers, as shown in table 1.
Documented variation between first wave providers on 
additional services included free access to local exercise 
facilities, signposting to NHS choices for weight loss25 
and free access to Slimming World online.26 Provision 
Table 1 First wave intervention delivery approach across providers
National providers
A B C D
Core sessions Six group closed core 
sessions (of 90 min), held 
on alternate weeks
Six group sessions, held 
weekly
Four group core sessions 
(of 90 min), held weekly
One (individual session) 
and seven group sessions 
(of 60–90 min), held 
weekly
Follow-up/
maintenance 
sessions
One individual review 
session (of 60 min) held at 
month 3
Four open group 
maintenance sessions (of 
60 min)
Four sessions, held 
fortnightly Six sessions 
held monthly
Nine maintenance 
sessions, held monthly
Six programmed support 
contacts over the 
12 months of the Diabetes 
Prevention Programme, 
held at months 2, 3, 4, 5, 
6, 9 and 12
Review sessions Follow-up
reviews, held at 6 and 
9 months
Two review sessions
 o
n
 28 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019467 on 21 February 2018. Downloaded from 
 5Penn L, et al. BMJ Open 2018;8:e019467. doi:10.1136/bmjopen-2017-019467
Open Access
of single sex groups and accessible venues, to address 
equality issues, were set out in provider plans. However, 
it remained unclear how realisation of different adapta-
tions to the programme will be triggered or how they will 
be prioritised within a proportionate universalism frame-
work (as outlined in the Marmot Review).27 The wide 
range of possible adaptations, presented by providers, 
risks accountability in the absence of explicit plans to 
monitor the impact of specific adaptations. Document 
review identified that fidelity procedures, including staff 
qualifications and training, were assigned as provider 
responsibilities. There were limited contractually agreed 
fidelity procedures that were applied in common across 
all providers.
A summary of qualitative research participant inter-
views and focus groups is provided in table 2.
Themes identified through qualitative research of 
stakeholder perspectives included: social factors, such as 
group support, socialising and influence of service users 
on other people; service specification, such as flexibility 
and use of intervention scripts, tailoring, adaptation 
and progressive variation in intervention provision; and 
fidelity procedures, including staff qualities and training, 
mentoring and refresher training. Service users benefited 
from the peer support of their DPP group and some spoke 
about social support from family and friends. They also 
highlighted some challenges and opportunities in the 
social nature of the DPP target behaviours. Intervention 
delivery staff spoke about flexibility in their delivery of 
the intervention and how this might change with context 
and experience. Staff qualities and fidelity procedures 
were also discussed, with consensus on the importance 
of these. Illustrative quotes for these themes are provided 
in box 2.
Concerns about sustainability, post-NHS DPP inter-
vention provision and the importance of linkage with 
existing services were important themes. The opportunity 
to make use of the NHS DPP to promote health messages 
was highlighted. Illustrative quotes for these themes are 
provided in box 3.
risk assessment procedures and recruitment pathways
Document review showed that referral was via primary 
care or NHS Health Checks28 in all demonstrator sites and 
some also reported community-based recruitment, but 
allocation of recruitment responsibilities lacked clarity. 
Risk communication29 30 procedures were reported in 
one demonstrator site only. In the NHS DPP first wave, 
agreements with local health economies covered referral 
targets, with recruitment being clarified as a provider 
responsibility, hence partnership working was required. 
In the demonstrator site phase, community-based aware-
ness raising in black and minority ethnic communities 
was included in baseline documentation. Communi-
ty-based recruitment was contracted in four of the first 
wave areas (one for each provider) in order to consider 
additional future recruitment approaches for harder to 
reach groups.
Table 2 Qualitative research participants
Stakeholder group Individual interviews Focus groups (WS1) Focus groups (WS2)
Local commissioners n=13 (6 m, 7 f) 26–49 min n=6 (3 m, 3 f) n=21 (6 m, 14 f)
Referrers/healthcare professionals n=10 (5 m, 5 f) 23–45 min n=2 (1 m, 1 f)
Intervention deliverers (demonstrator 
phase)
n=15 (4 m, 11 f) 21–65 min n=6 (1 m, 5 f)
First wave provider key contacts n=3 (1 m, 2 f) 60 min n=3 (1 m, 2 f)
Service users (demonstrator phase) n=20 (9 m, 11 f) 23–39 min n=1 (1 f) –
f, female; m, male; WS, Workshops at Newcastle University London campus: WS1: (23 March 2016): WS2- (12 December 2016).
box 3 sustainability, postintervention provision, linkage 
with existing services and opportunity to promote health 
messages: qualitative research themes and illustrative 
quotes
Sustainability, postintervention provision: ‘There are enormous funding 
pressures on so many of our services that to argue for investment in 
prevention is quite a difficult ask’. (Interview, local commissioner 7, 
female, age 60 years)
‘Yes, and if it’s not worked, there should be something else, because 
that’s what the whole point is isn’t it, it’s to try and stop this diabetes 
epidemic? To try to reduce the amount of NHS time that will need to 
be spent on people who become diabetic and the problems that that 
causes’. (Interview, service user 19, female, age 66 years)
‘I feel healthier, I feel more positive and I feel very determined not to 
let this thing happen to me if I can do anything about it’. (Interview, 
service user 3, female, age 61 years)
Linkage with existing services: ‘We don’t have a lot of money to 
commission these things, we’re just looking at the best ways of 
working, so we’re linking it to other things as a borough’. (Focus 
group, workshop 2)
‘It’s trying to bring your local services along that same journey, 
isn’t it so they’re working together right from the very start of the 
programme’. (Focus group, workshop 2)
Opportunity to promote health messages: ‘It’s an additional resource 
in the community that people are more networked and actually link in 
with each other’. (Focus group, workshop 2)
‘Maybe [add] conversations about how they could be sharing their 
knowledge with their family- are they improving their family meals’. 
(Focus group, workshop 1)
‘Using the Diabetes Prevention Programme as a launch pad for a 
wider public debate on food, sugar tax, population level risk’. (Local 
commissioner 4, male, age 63 years)
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Qualitative research highlighted respondents concerns 
and challenges around referral and uptake including: the 
crucial role of primary care in recruitment, allocation of 
resources and training to support this role and effective 
risk communication; contextual factors, equality issues 
and the need for community based recruitment; and the 
difficulties of intervention provision in sparsely popu-
lated rural areas. Local commissioners flagged the benefit 
of shared learning to maximise efficiency in the referral 
pathway and the difficulties in understanding the allo-
cation of roles and responsibilities. Illustrative quotes in 
support of these qualitative research themes are provided 
in box 4.
In the demonstrator site phase risk score use and blood 
testing were documented, with the Diabetes UK risk 
score10 and HbA1c blood test being the usual measures. 
The service specification for the NHS DPP first wave 
relied exclusively on assessment of NDH as the criterion 
to determine high risk for intervention eligibility, and risk 
scores were not used.
Data collection to support monitoring and evaluation
Demonstrator site data collection was usually docu-
mented in terms of primary care data systems. First wave 
providers were contracted to collect a ‘minimum data set’ 
of items. However, there were uncertainties regarding 
data collection procedures and measurement proto-
cols, with potential for variation between providers. We 
noted variation between providers in collection of data 
additional to items in the minimum data set (such as 
dietary data). First wave providers were required to notify 
general practitioners when people were discharged from 
the NHS DPP and to liaise locally to ensure these data 
could be integrated in clinical systems. However, in focus 
groups with local commissioners, reporting procedures to 
inform timely local public health monitoring of the NHS 
DPP was raised, and the need for better data sharing and 
timely feedback to monitor local intervention progress, 
in relation to referral targets and process outcomes, was 
a strong theme in focus group discussions. Timescales in 
relation to learning from the demonstrator sites were also 
highlighted, with the pace of roll-out being viewed as an 
important limitation and missed opportunity.
Documentary information on data collection to 
monitor recruitment routes and intervention uptake was 
limited. This limitation was also identified through qual-
itative research on recruitment in relation to subgroups 
(eg, gender and ethnicity) and type of contact (eg, 
mail-drop, face to face or phone). However, the need to 
balance data collection with respondent burden to avoid 
detrimental impact on participant engagement, espe-
cially where there might be language or literacy issues, 
was highlighted.
We identified risk assessment and referral costs as 
contributors to the overall costs and efficiency of NHS 
DPP implementation. Attribution of these costs (eg, 
to primary care) and how they might be included in 
economic analysis of the NHS DPP in later phases was 
unclear. Comparison of the NHS DPP minimum data set 
with incident risk score data is detailed in table 2. In qual-
itative research local commissioners and intervention 
box 4 risk assessment procedures and recruitment 
pathways: qualitative research themes and illustrative 
quotes
Crucial role of primary care in recruitment, allocation of 
supportive resource and effective risk communication:
‘The ones [GP practices] with incentives have got started much 
quicker’. (Focus group workshop 2)
‘The real driver for that response rate has been the fact that letters 
have been from GP practices’. (Focus group workshop 2)
‘Push the idea that it is in the GPs financial interest also to get 
involved’. (Focus group workshop 2)
‘Because sometimes, the practice managers can be the gate keepers 
and … the practice manager says [to a referrer] “No, you’ve got to do 
your influenza clinic” ’. (Focus group workshop 1)
‘If you’ve only got one side driving it’s going to be a struggle’. (Focus 
group workshop 2)
‘Health professionals across the board should be having much more 
information in their minds so they can have that brief intervention, that 
brief every contact counting’. (Focus group workshop 1)
‘ For me, one of the main elements is not the eligibility… It’s the 
communication of risk. In terms of a conversion rate I think that’s 
really, really important’. (Focus group workshop 2)
Contextual challenges, equality and community-based 
recruitment:
‘We have a huge geographical area… with a very dispersed 
population and we’re also very remote. We don’t have providers 
knocking on our door because it [intervention delivery across a wide 
rural area] is not viable’. (Focus group workshop 2)
‘We are getting what they call the low hanging fruit to start with. The 
longer it goes on the harder it is going to be to identify people and to 
get them to engage’. (Interview, local commissioner 3, female, age 
58 years)
‘If we really want to target the clients that we really want to engage 
with, it’s about…working with those community leaders’. (Focus group 
workshop 1)
‘We’re using community based settings all over…we try to make sure 
they’re on a bus route’. (Interview, intervention deliverer 14, female 
age 52 years)
Local commissioners, shared learning and allocation of 
roles and responsibilities:
‘I would have a plea as to a repository of information, so that we can 
look at different letter templates that have been successful’. (Focus 
group workshop 2)
‘I have come along today and listened to people with real experience 
in it… lessons learnt, different uptakes… none of that’s shared and 
that sort of sharing would save us a load of work’. (Focus group 
workshop 2)
‘We are going to change our referral pathway and get practices to 
phone patients because we have learnt from other areas there’s a 
much higher conversion rate’. (Focus group workshop 2)
‘What was the role of NHS England? What was the role of the local 
partnership? What was the role of the provider? That’s a whole roles 
and responsibility difficulty around the tripartite arrangement. For me 
if something goes wrong, I’d be thinking, “Well, how do you deal with 
it?” ’. (Focus group workshop 2)
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providers expressed concerns about HbA1c testing and 
eligibility including: what to do when test values were 
just over the upper limit, when there were differences 
in repeated tests and when there were discrepancies 
between point of care values compared with standard 
venous blood test values, which could adversely impact 
outcome evaluation31 32 (iii)). New guidance on eligi-
bility criteria and HbA1c measures was issued in early 
2017 by the NHS DPP implementation team, following 
a consultative exercise, to address eligibility issues. Illus-
trative quotes in support of these qualitative research 
themes are provided in box 5.
DIsCussIOn
Principal findings
The NHS DPP first wave specification reflected the 
evidence base10 and provided a service framework 
with sufficient flexibility to support balance in inter-
vention delivery between consistency and limited vari-
ation to accommodate local contextual and cultural 
adaptations.33 Providers, with capacity to deliver NHS 
DPP compliant interventions on a national scale, were 
commissioned to deliver the intervention in 27 first 
wave areas. Responsibility for detailed session planning 
was devolved to intervention providers. Procedures to 
ensure fidelity of intervention delivery lacked clarity 
and were reliant on provider driven (internal verifica-
tion) procedures with34 inevitable variation between 
providers. How variations in intervention provision 
(eg, to accommodate cultural adaptations) within 
each provider organisation were prioritised, triggered, 
actioned and monitored27 were unclear and this omis-
sion is likely to compound uncertainties regarding 
fidelity of intervention delivery and adversely impact 
on effectiveness, evaluation and monitoring for service 
improvement.
First wave NHS DPP risk assessment procedures 
differed from NICE guidance.10 Recruitment of people 
with an existing primary care NDH record might be 
considered a reasonable and pragmatic first wave 
strategy, because these people are known to be at 
risk of T2D. However, modification will be needed in 
subsequent phases to improve consistency and equity 
in relation to risk stratification. Concerns regarding 
reliability of point of care HbA1c testing will affect 
outcome evaluation.31 32 Distribution of stakeholder 
responsibilities and resources to support recruitment, 
staff training, linkage to other services, sustainability 
of the programme and behaviour change maintenance 
require clarification to maximise likely effectiveness of 
the programme going forward.
Collection of a common ‘minimum data set’ by 
providers supported basic monitoring, but additions to 
these data, such as including quality of life assessment35 
(now added) and data on routes to recruitment, risk 
factors and participant behaviours, will be needed to 
support evaluation and programme improvement.
strengths and limitations of the evaluation
We applied a systematic approach, in both demonstrator 
site and first wave evaluations, to appraise the baseline 
programme documents. We appraised elements across 
box 5 Monitoring, evaluation and data collection: 
qualitative research themes and illustrative quotes
Data sharing and timely feedback to monitor local 
intervention progress and learn from the demonstrator 
sites
‘NHS England have commissioned a CSU (commissioning support unit) 
to do a lot of data reporting, and extraction from the providers. So I’ll 
be expecting to have regular reporting from them. I think the intention, 
as well, is to have relatively regular meetings with the provider 
themselves. With the coding that we have on [GP data base]we should 
be able to see on there certainly the number of people who’ve been 
referred, and then there should be coding going back into [GP data] I 
would hope as well. So we should be able to see the number of people 
who’ve completed.
‘In terms of the quality of the actual intervention itself, I think we will 
be probably relying on patient questionnaires, and other qualitative 
feedback that’s provided. I think it’s within the service specification, 
and data reporting, that they need to do that. So we’ll probably rely on 
that I think’. (Interview, local commissioner 2, male, age 33 years)
‘You would look at the outcomes of the service that was being 
provided and saying, “If that is not achieving the long-term changes 
then do we need to look at changing it or trying something different? 
That is the same I think with most commissioning, if the service you 
are commissioning isn’t providing the outcomes you need it to achieve 
then you have to look again” ’. (Interview, local commissioner 3, male 
age 58 years)
‘I don’t think the timescales have been good at all. I’m very 
disappointed that the demonstrator sites haven’t been demonstrator 
sites at all, because we’re barely up and running and the national 
provider’s almost been procured. I don’t know where all the learning is 
going. I think if the pilot programmes had been allowed a little bit more 
time to set up and to run, and then for them to conclude, and then take 
the learning from that to fashion, nationally, what it is that’s going to 
be provided then I think that would have been a lot better, but I think 
this short-termism has not enabled people to really get to grips with 
learning’. (Interview, local commissioner 1, female, age 57 years)
Data to monitor recruitment routes and intervention uptake
‘If we wanted to do some local health equity audit and look at whether 
the right people were getting into the right programmes, would we 
actually get the level of data that would enable us to do that? I think 
that at that stage NHS England said they didn’t know. As far as I am 
aware that is probably still the case’. (Focus group workshop 2)
HbA1c testing and values
‘And out of 307 [number referred] 10 have been ineligible for the 
programme after they’ve gone through the test, because the provider 
will test them again, their HbA1c’. (Focus group workshop 2)
‘I mean there is the group who have just slipped into diabetes. That is 
a tricky area as well because they can’t be offered the programme’. 
(Focus group workshop 2)
‘The problem is when you get a different result from a point-of-care 
(HbA1c) testing from the venous testing that’s gone on beforehand 
through a GP, or other parts of primary care’. (Focus group workshop 
2)
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the entire programme of activities from awareness raising 
to follow-up, avoiding a narrow focus on intervention 
delivery. We used recommendations in NICE guidance10 
to structure the review and appraisal of service spec-
ification and provider documents, thus assessing the 
service specification in relation to the evidence base: an 
approach that might be transferable to other intervention 
programmes. The decision to start with a demonstrator 
site phase was an innovative and potentially influential 
initiative. However, the pace at which the first wave of 
the national programme was rolled out, set against the 
time needed to conduct meaningful appraisal, made it 
difficult to maximise ‘learning from the demonstrator 
sites’ to inform the first wave NHS DPP, although this 
was the stated aim of the demonstrator site phase1 and of 
our evaluation. We explored procedures for assessment 
of fidelity in intervention delivery17 and worked towards 
the development of tools suitable for common assessment 
of feasibility, acceptability and fidelity that could be used 
across different providers within the programme.
A strength of our qualitative research was the inclu-
sion of four stakeholder groups (local commissioners, 
healthcare professionals, intervention delivery staff and 
service users). Conducting interviews by phone maxi-
mised resource use and delivering focus groups in a 
workshop setting allowed several interactive discussions 
to take place within the time available for the project, but 
restricted the number of participants. The focus of our 
evaluation, at this early stage of programme roll-out, was 
on the broad issues of national programme specification 
and implementation strategies. Detailed exploration of 
site specific organisational strategies, and variations in 
these, that aimed to facilitate uptake of the programme 
in different localities will be of increasing interest as the 
programme becomes embedded across England. In indi-
vidual interviews and interactive focus group discussions, 
stakeholders highlighted the importance of primary 
care in programme mobilisation. As the programme is 
rolled out across England, and it becomes embedded in 
healthcare, evaluation of local organisational strategies 
and their effect on implementation will be of increasing 
interest.
Evaluation findings were used to formulate recom-
mendations in summaries of detailed reports that 
were supplied to the NHS DPP Management Group at 
prespecified intervals, as part of the commissioned eval-
uation requirements. The Management Group (inter-
vention commissioners) categorised responses to these 
recommendations as: A) Recommendations imple-
mented before the evaluation report was received; B) 
Recommendations implemented in response to the eval-
uation; C) Recommendations that might be considered 
for the next round of procurement; D) Recommenda-
tions deferred. Provision of recommendations, based on 
findings, was in line with the MRC (2008) framework 
for the implementation phase in development and eval-
uation of complex interventions to improve health.12 
Liaison with the Management Group with regard to 
these recommendations, including dissemination 
through teleconference presentation and discussion, 
and of collation of tables to formalise their response 
to recommendations, was a strength of our formative 
evaluation that may guide subsequent implementation 
phases and facilitate the assessment of impact in imple-
mentation evaluation.
strengths and limitations in relation to other studies
There is strong trial evidence for the effectiveness of 
behavioural intervention, with content and goals similar 
to those of the NHS DPP intervention, to reduce the risk 
of T2D in people at high risk.10 Thus, the main challenge 
for the NHS DPP is in its implementation, especially with 
the ambitious scale of the project, with expected 100 000 
places to be made available each year from 2020 and pace 
of roll-out.36 To support implementation, there is a need 
to consider local contextual evidence.37 Although the 
demonstrator site phase was primed to do this, the pace 
of roll-out restricted the utility of this phase.
The first wave NHS DPP was commissioned nationally 
to be delivered by four provider organisations. Detailed 
evaluation of local implementation of this model is of 
interest but was not the focus of our early phase evalua-
tion. Other implementation models have been employed 
notably in Finland,38 the USA36 and Germany.39 The 
NHS DPP is specified according to a service framework, 
which devolves responsibilities that allow intervention 
providers some discretion on the balance between facili-
tator autonomy, which may maintain motivation,40 41 and 
structured session plans, which may support consistency 
in intervention delivery. This framework specification 
model leads to inevitable variation between intervention 
providers in their approach. In the NHS DPP, variations 
between providers are controlled by the detailed service 
specification and number (four) of national providers. It 
is unclear how the balance between consistency and flexi-
bility in intervention provision impacts effectiveness.
European guidelines for T2D prevention recommend 
reference to behaviour change theories and techniques 
in the design of appropriate interventions.42 The Good 
Ageing in Lahti Region (GOAL) study from Finland,43 
which succeeded the DPS, included the Health Action 
Process Approach (HAPA) behavioural theory.44 45 This 
translational study informed the Greater Green Triangle 
(GGT) project in Victoria, Australia,46 which in turn influ-
enced more extensive diabetes prevention programmes 
in Australia.47 48 Both the GOAL43 and GGT46 ‘real world’ 
programmes demonstrated likely effectiveness. However, 
a review of reviews found increased effectiveness of 
physical activity and dietary interventions in people at 
risk of T2D to be associated with a cluster of behaviour 
change techniques rather than a particular theory.49 
The HAPA model is included in the NHS DPP change 
theory, although it is not clear how it might be actioned. 
Listing behaviour change techniques with specific associ-
ated delivery strategies might be more effective and more 
informative for future evaluation.
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Early diabetes prevention trial experiences suggest that 
their format, which included personalised individual 
behavioural consultation,50 mean intervention dura-
tion of around 3 years and the resource and respondent 
burden of risk assessment and detailed data collection, 
limits the external validity and utility of these research 
findings for large-scale implementation.51–53 In particular, 
the shift to more pragmatic risk assessment and group-
based intervention delivery is likely to impact adversely 
on effectiveness.54
Diabetes incidence as the outcome of interest 
requires long-term follow-up. The NHS DPP stipulates a 
minimum 9 months of intervention, but longer follow-up 
is needed to properly assess diabetes incidence over 
time.10 Changes to the National Diabetes Audit that are 
designed to facilitate longer term follow-up of NHS DPP 
service users and others with NDH have been imple-
mented, thus providing support for long-term evalua-
tion of the initiative. In other translational programmes, 
intermediate health and behavioural outcomes have 
been used for interim evaluation within a shorter time-
frame.10 Weight loss is a simple and objective candidate 
for interim outcome analyses, but an assumption that 
weight loss will equate to prevention of T2D, similar to 
that achieved in trials, in differently identified high-risk 
populations is, flawed.55 It seems probable, for example, 
that the physiological differences between a population 
identified by IGT and a population identified by IFG 
(or raised HbA1c) will affect their overall capacity to 
benefit from lifestyle intervention and thus impact on 
its effectiveness.56 Although the incomplete overlap 
between different NDH categories was illustrated in a 
recent review, the implications of these different NDH 
categories for intervention effectiveness were not drawn 
out in this paper.57
Meaning of the study: possible explanations and implications 
for clinicians and policymakers
The decision by the NHS DPP Management Group 
to first focus on people already identified with NDH 
through routine clinical practice is understandable, 
because these people are already known to be at risk 
of T2D. Risk assessment as advocated in NICE guid-
ance (PH38) was a two-stage process.10 In suggesting 
this two-stage approach, the NICE programme devel-
opment group (PDG) acknowledged the scarcity of 
evidence in this area and included research recom-
mendations identification and monitoring (1). Over 
time, the NHS DPP could provide opportunities to 
investigate pragmatic, efficient and equitable recruit-
ment procedures and criteria to assess high risk and 
capacity to benefit from intervention to prevent T2D.
High-risk and population level approaches to T2D 
prevention are included in the current NHS England 
policy.1 58 59 However, the engagement of people at high 
risk in intensive behavioural intervention may impact on 
others within their sphere of influence,60 61 thus devel-
opment and evaluation of a high-risk approach should 
take into account opportunities to use individual engage-
ment in healthier lifestyles for wider health and social 
benefits.62
Our experience reflects the more general chal-
lenges inherent in conducting external evaluation of 
programmes that are continually evolving. We sought 
to improve the utility of this formative evaluation by 
supplying recommendations based on findings to 
commissioners, and we were able to elicit their formal 
response to each recommendation.13
unanswered questions and future research
A formal outcome evaluation for effectiveness and cost-ef-
fectiveness of the NHS DPP implementation has been 
commissioned by the NIHR.63 As part of the formative 
evaluation, we drafted tools to support feasibility, accept-
ability and fidelity assessment of the NHS DPP interven-
tion and improve data collection on recruitment routes 
to inform equity of the service provision.
Capacity to benefit from lifestyle intervention may be 
affected by multiple factors, and we welcome the oppor-
tunity that the national scale NHS DPP, if supported by 
improved fidelity and data procedures, could afford to 
push forward empirical research in this respect.
As a standard ‘usual care’ comparator, the NHS DPP 
nationally commissioned service has potential to support 
further research on lifestyle intervention for prevention 
of T2D, which could not otherwise be achieved, given the 
diversity in implementation and evaluation inherent in 
locally commissioned programmes.
COnCLusIOn
When fully implemented the NHS DPP will provide an 
evidence-based lifestyle intervention for prevention 
of T2D in adults at high risk, with provider capacity to 
deliver the intervention on a national scale. Formative 
evaluation of first wave NHS DPP implementation found 
that the intervention specification reflected current 
evidence, while allowing balance between consistency 
and contextual variation in intervention delivery, with 
detailed session planning devolved to providers.
Limitations in intervention fidelity assessment and data 
collection procedures are likely to impact adversely on 
intervention effectiveness. Improvements are needed 
to ensure the intervention is delivered as intended with 
support for evaluation and programme improvement.
Inviting people already identified as at risk (with NDH 
record) to participate in the NHS DPP may be an appro-
priate first wave strategy. However, compliance with NICE 
guidance for two-stage assessment of high risk will be 
needed to improve consistency, equity and cost-effective-
ness for future implementation phases.
It is unlikely that one intervention model alone will 
engage all those at high risk or be equally effective for all 
participants. The national scale and detailed framework 
specification of the NHS DPP, if supported by improved 
fidelity assurance and data collection procedures, could 
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afford opportunities to design and test variations to 
the standard intervention to maximise its impact. To 
facilitate such empirical research, clear differentiation 
between planned and unplanned variations within the 
national programme is needed, emphasising the need 
for improved fidelity assessment and data collection 
procedures.
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